To meet the logistics needs of today’s pharmaceutical and healthcare customers, it takes a carrier with a strong pharma background. And Swiss WorldCargo is the right carrier to do so. From providing a wide array of sophisticated, temperature controlled container solutions to leveraging the short tarmac times at Zurich airport, Swiss WorldCargo provides the right infrastructure, facilities and solutions to manage the most diverse requirements. 

Various Swiss WorldCargo products offer solutions that meet the wide-ranging needs of our pharmaceutical and healthcare customers. 

  • SWISS °Celsius Active allows for transportation in a wide range of active temperature-controlled containers in temperature ranges from -20 °C to +20 °C. 
  • SWISS °Celsius Passive offers a choice between four official IATA temperature ranges varying between -60°C and +25°C, alongside standardized processes ensuring the proper environment for storage. 
  • SWISS °Celsius Passive Solutions offers standardized processes to ensure that cargo is stored in a required temperature environment. Uninterrupted cool chain door-to-door is also ensured.
Go to article: Home | EDS: Treating a medical zebraGo to article: Scandinavian Health LtdGo to article: EditorialGo to article: Emirates SkyCargoGo to article: ContentsGo to article: Nolato Company Insight Go to article: NolatoGo to article: NewsGo to article: The pharma industry briefingGo to article: Subcuject Company Insight Go to article: SubcujectGo to article: Horizon 2020: a look back at flagship EU pharma projectsGo to article: SanofiGo to article: Sky high: should US drug prices fall in-line with the rest of the world?Go to article: Nipro PharmapackagingGo to article: Q&A: talking drug quality with Valisure, the first analytical pharmacyGo to article: NemeraGo to article: What does ‘ageing’ mean when it comes to drug development? Go to article: Swiss WorldCargoGo to article: Manufacturing medicines in space: how astronauts will make their own drugs Go to article: MimotopesGo to article: Aducanumab’s surprising revival: how an Alzheimer’s drug came back from the deadGo to article: Molnar Company Insight Go to article: Molnar-InstituteGo to article: Ehlers-Danlos syndrome: The zebra in the roomGo to article: KugelmeiersGo to article: Stop ignoring the two billion: pharma’s role in expanding access to medicineGo to article: SkyepharmaGo to article: IDMP: turning attention to patient benefitsGo to article: Deals in brief powered by GlobalDataGo to article: The key list powered by GlobalDataGo to article: EventsGo to article: Next issue